uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
Form 144 notice by uniQure N.V. (QURE) reporting a proposed sale of 3,000 ordinary shares through Citigroup Global Markets on 09/24/2025 with an aggregate market value of $120,000.00. The filing lists total shares outstanding as 54,866,930. The securities were acquired and are to be sold on 09/24/2025 as the result of a stock option exercise and sale pursuant to a Rule 10b5-1 plan, and payment for the acquisition was in cash. The filer indicates no securities sold by the same person in the past three months and includes the standard representation that the person does not possess undisclosed material adverse information.
uniQure N.V. (QURE) reported a Form 144 notification showing the proposed sale of 226,316 ordinary shares by a person associated with the company. The shares are to be sold through Citigroup Global Markets on 09/24/2025 with an aggregate market value of $9,381,750.00. The filing states these shares were acquired on 09/24/2025 via stock option exercise and sale pursuant to a Rule 10b5-1 plan, and payment was made in cash. The issuer has 54,866,930 shares outstanding, so the shares notified represent approximately 0.41% of outstanding stock. The filer indicates no other sales in the prior three months and includes the standard certification that no undisclosed material information is known.
uniQure N.V. is offering up to $200,000,000 of ordinary shares and pre-funded warrants, with ordinary shares listed on Nasdaq under the ticker QURE and a reported last sale price of $47.50 on September 24, 2025. The supplement highlights positive pivotal Phase I/II topline 36-month data for AMT-130 in Huntington's disease: a 75% slowing in disease progression by cUHDRS (p=0.003) and a 60% slowing by TFC (p=0.033) versus a propensity score‑matched external control, and the company plans a pre‑BLA meeting with the FDA and intends to submit a BLA in Q1 2026. Other programs: AMT-260 (MTLE) shows early seizure reduction signal; AMT-191 (Fabry) reports sustained GLA activity in cohort 1; AMT-162 (SOD1-ALS) enrollment is voluntarily paused after a dose‑limiting toxicity in cohort 2 while data are evaluated. The company disclosed a Dutch tax assessment related to a 2023 royalty financing upfront payment and expects a current tax liability in the mid single- to low double-digit millions. Financials show a net tangible book value deficit of $(114) million as of June 30, 2025; proceeds are intended for commercialization readiness, potential AMT-130 launch, development, and general corporate purposes.
uniQure N.V. reported it entered into a material amendment to its loan arrangements with Hercules Capital. The filing states an Amendment No. 3 to the Third Amended and Restated Loan and Security Agreement was executed September 22, 2025 by uniQure biopharma, B.V., uniQure, Inc., uniQure IP B.V., the company and Hercules Capital, Inc.
The event is listed as both an entry into a material definitive agreement and the creation of a direct financial obligation, and the filing includes the signed exhibit for the amendment. The notice is signed by Jeannette Potts, Chief Legal and Compliance Officer, dated September 24, 2025.
uniQure reported clinical updates for AMT-130 in an 8-K and furnished a press release (Exhibit 99.1) and an investor webcast. The company said FDA discussions allow cohorts 1 and 2 from the Phase I/II studies to be compared to a propensity score-matched external control from the Enroll-HD natural history dataset under a prespecified statistical analysis plan, which may serve as the primary basis for a BLA submission. The company added two protocols to pool data across the U.S. and EU studies and to prespecify the pivotal comparison versus the Enroll-HD external control. Reported outcomes in the release include a statistically significant 75% slowing of disease progression on a composite UHDRS measure, a 60% slowing on Total Functional Capacity, favorable trends in motor and cognitive secondary endpoints including Symbol Digit Modalities Test, and a mean reduction in cerebrospinal fluid neurofilament light protein. The release announced an investor call and a webcast available for replay for 90 days.
uniQure N.V. (QURE): Nantahala and its principals report a 3.75% beneficial stake. As of June 30, 2025, Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 2,051,852 ordinary shares, representing 3.75% of the outstanding class. The filing states that all reported shares are held by funds and separately managed accounts under Nantahala's control and that the Reporting Persons have shared voting and shared dispositive power over those shares, with no sole voting or dispositive power reported. The filing is made under Schedule 13G classification for an investment adviser and indicates the position is held in the ordinary course of business and not for the purpose of changing control.
Vestal Point Capital, LP and Ryan Wilder reported beneficial ownership of 3,700,000 ordinary shares of uniQure N.V., representing 6.8% of the outstanding class. The shares are directly held by a Vestal Point-managed fund and a managed account; Mr. Wilder is the Chief Investment Officer and managing partner of the investment manager and reports shared voting and dispositive power over the shares. The percent calculation uses 54,748,496 ordinary shares outstanding as of May 6, 2025. The filing states the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
RTW Investments, LP and Roderick Wong report a passive 9.4% stake in uniQure (QURE), holding 5,158,231 ordinary shares. The holdings are held directly by the RTW Funds and RTW Investments and Dr. Wong report shared voting and dispositive power over all 5,158,231 shares and report no sole voting or dispositive power. The percentage is calculated using 54,865,673 shares outstanding as reported for the period cited in the filing. The statement is made on a Schedule 13G basis and includes a certification that the shares were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.
Avoro Capital Advisors LLC and Behzad Aghazadeh report holding 3,625,000 ordinary shares of uniQure N.V., representing 6.6% of the outstanding class. The percentage is calculated using 54,748,496 ordinary shares outstanding as of May 6, 2025. The filing states the shares were acquired and are held for investment purposes on behalf of Avoro Life Sciences Fund LLC, and that the reporting persons have sole voting and sole dispositive power over the reported shares. The statement also notes the filing should not be construed as an admission of beneficial ownership for Section 13 purposes. Avoro Life Sciences Fund LLC is identified as having the right to receive dividends or sale proceeds for the position.
Aberdeen Group plc and subsidiary abrdn Inc. have filed a Schedule 13G disclosing a new passive position in uniQure N.V. (QURE).
- Shares owned: 2,750,714 ordinary shares
- Ownership: 5.02 % of the outstanding class
- Voting/Dispositive power: 0 sole / 2,750,714 shared
- Event date: 30 Jun 2025 | Filing signed: 30 Jul 2025
- SEC classifications: Aberdeen – Parent Holding Company (HC); abrdn Inc. – Investment Adviser & Corporation (IA, CO)
- Certification affirms the stake was acquired in the ordinary course and not intended to influence control.
The filing adds a sizeable institutional holder to uniQure’s share register, but because it is a 13G (passive) submission, it carries no stated activist intent.